设为首页 加入收藏

TOP

Ketorolac 60mg 25X2ml(酮咯酸氨丁三醇注射剂)
药店国别  
产地国家 美国 
处 方 药: 是 
所属类别 60毫克 25瓶X2毫升 
包装规格 60毫克 25瓶X2毫升 
计价单位: 盒 
生产厂家中文参考译名:
SAGENT PHARMACEUTICALS INC
生产厂家英文名:
SAGENT PHARMACEUTICALS INC
该药品相关信息网址1:
https://www.drugs.com/pro/ketorolac.html
该药品相关信息网址2:
该药品相关信息网址3:
原产地英文商品名:
KETOROLAC 60MG SDV 25X2ML
原产地英文药品名:
KETOROLAC TROMETHAMINE
中文参考商品译名:
KETOROLAC注射剂 60毫克 25瓶X2毫升
中文参考药品译名:
酮咯酸氨丁三醇
曾用名:
简介:

 

部份中文酮咯酸氨丁三醇处方资料(仅供参考)
商品名:Ketorolac
英文名:KETOROLAC TROMETHAMINE
中文名:酮咯酸氨丁三醇
药品介绍
别名:酮咯酸;酮咯酸氨丁三醇 ,痛力克,痛力消,酮咯酸三羟甲氨基甲基烷,酮洛来克
外文名:Ketorolac,KETOROL,Ketanov, TORADOL, Toratex, Tromethamine
适应症
用于一切痛症,适用于短期消除创伤和术后疼痛、肿痛、剧烈痛及各种原因引起的疼痛。片剂或注射液可用于缓解中度至剧烈的术后疼痛,包括腹部、胸部、妇科、口腔、矫形及泌尿科手术。此外,亦可缓解急性肾胶痛、胆绞痛、牙痛、创伤痛、三叉神经痛、癌症内脏痛,以及以往一切需用吗啡或哌替啶才能生效的各种疼痛症。
用量用法
口服:每次10mg,每日1~4次,剧痛患者可增至每次20~30mg,每日3~4次。肌注:每次30~90mg,术后中度或剧痛者以肌注30mg为宜,剧痛者可肌注60mg,继而每小时肌注15~30mg。对65岁以上或肾功能不全者减量,每日总剂量不应超过60mg。
注意事项
长期应用时,极个别患者可引起胃肠道溃疡或出血症状,发生率与阿司匹林相当。还可出现胃肠道疼痛、消化不良、腹泻、口干、嗜睡、头痛、眩晕、汗多等。心、肝、肾患者和高血压患者慎用;对阿司匹林过敏者、活动性溃疡病、有出血倾向者、孕妇、乳妇、产妇及16岁以下儿童忌用。不宜与其他非甾体类抗炎药并用,以免增加副反应。
包装
KETOROLAC 60 MG SDV 25X2 ML  KETOROLAC TROMETHAMINE SAGENT PHARMACEUTICALS INC  25021070102
KETOROLAC 15 MG SDV 25X1 ML KETOROLAC TROMETHAMINE  SAGENT PHARMACEUTICALS INC  25021070001
-------------------------------------------------
KETOROLAC TROMETHAMINE- ketorolac tromethamine injection
Pfizer Laboratories Div Pfizer Inc
Each mL of Ketorolac Tromethamine Ophthalmic Solution contains: Active: Ketorolac tromethamine 0.4%. Preservative: Benzalkonium chloride 0.006%. Inactives: Edetate disodium dihydrate 0.015%; octoxynol 40; sodium chloride; hydrochloric acid and/or sodium hydroxide to adjust the pH; and water for injection.
TORADOL ORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOL ORAL and ketorolac tromethamine should not exceed 5 days.
Rx Only
WARNING
Ketorolac Tromethamine Injection USP, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of oral ketorolac tromethamine and ketorolac tromethamine injection should not exceed 5 days.
Ketorolac tromethamine is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of oral ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will increase the risk of developing serious adverse events.
GASTROINTESTINAL RISK
Ketorolac tromethamine can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).
CARDIOVASCULAR RISK
NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS and CLINICAL TRIALS).
Ketorolac tromethamine is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS ).
RENAL RISK
Ketorolac tromethamine is CONTRAINDICATED in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion (see WARNINGS).
RISK OF BLEEDING
Ketorolac tromethamine inhibits platelet function and is, therefore, CONTRAINDICATED in patients with suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see WARNINGS and PRECAUTIONS).
Ketorolac tromethamine is contraindicated as prophylactic analgesic before any major surgery.
INTRATHECAL OR EPIDURAL ADMINISTRATION
Ketorolac tromethamine is CONTRAINDICATED for intrathecal or epidural administration due to its alcohol content.
RISK DURING LABOR AND DELIVERY
The use of ketorolac tromethamine in labor and delivery is contraindicated because it may adversely affect fetal circulation and inhibit uterine contractions. The use of ketorolac tromethamine is contraindicated in nursing mothers because of the potential adverse effects of prostaglandin-inhibiting drugs on neonates.
CONCOMITANT USE WITH NSAIDs
Ketorolac tromethamine is CONTRAINDICATED in patients currently receiving aspirin or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects.
CLINICAL PHARMACOLOGY
Pharmacodynamics
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties. 

】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Ketorolac 15mg 25X1ml(酮咯酸氨.. 下一篇Tarlge Tablets 15mg(Mirogabalin..

相关栏目

最新文章

图片主题

热门文章

推荐文章